₹13,454 Cr
24.34
₹553 Cr
As on 13-Aug-2024 IST
₹-2.55
•
-0.30%
₹851.45
₹851.45
₹863.70
₹840.25
2,57,406
₹318.75 - 876.75
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| 55.63 | 17.63 | 21.43 | 89.93 | 8.77 | 33.90 | 26.93 |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Mid Cap
| 26.89 | -1.61 | 13.94 | 53.62 | 26.75 | 27.88 | 17.84 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| 45.55 | -36.11 | -31.13 | 58.62 | -24.59 | -8.62 | 24.69 |
|
BSE Mid Cap
| 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 | 48.13 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Jubilant Pharmova Ltd stood at ₹ 11,549 Cr as on 30-Jun-24
The share price of Jubilant Pharmova Ltd is ₹848.90 (NSE) and ₹844.70 (BSE) as of 13-Aug-2024 IST. Jubilant Pharmova Ltd has given a return of 8.77% in the last 3 years.
Jubilant Pharmova Ltd has a market capitalisation of ₹ 13,454 Cr as on 13-Aug-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Jubilant Pharmova Ltd is 2.28 times as on 13-Aug-2024, a 47% discount to its peers’ median range of 4.29 times.
The P/E ratio of Jubilant Pharmova Ltd is 24.34 times as on 13-Aug-2024, a 27% discount to its peers’ median range of 33.36 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jubilant Pharmova Ltd and enter the required number of quantities and click on buy to purchase the shares of Jubilant Pharmova Ltd.
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.
The promoters of Jubilant Pharmova Ltd are SPB TRUSTEE COMPANY PVT LTD and HSB TRUSTEE COMPANY PVT LTD. They collectively own 39.52 per cent of the total equity. The chairman of the company is Shyam S Bhartia
There is no promoter pledging in Jubilant Pharmova Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
33,841
|
|
|
25,812
|
|
|
24,740
|
|
|
24,056
|
| Jubilant Pharmova Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
6.35
|
|
Operating margin(%)
|
8.76
|
|
Net Margin(%)
|
7.56
|
|
Dividend yield(%)
|
0.59
|
Yes, TTM profit after tax of Jubilant Pharmova Ltd was ₹553 Cr.
₹13,454.48 Cr
₹6,847.70 Cr
₹552.80 Cr
₹956.80 Cr
₹3,414.10 Cr
50.68%
High
₹318.75 - 876.75
₹1.00
15,92,81,139
NSE: JUBLPHARMA, BSE: 530019
Gajraula, Uttar Pradesh
www.jubilantpharmova.com
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables,... Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India. Read more
Stocks 
Jubilant Pharmova Ltd.
Widely used:
